Answers are grounded in this paper and cite their sources.
Observational findings link brain glucose metabolism to cognitive decline risk, suggesting potential for therapeutic intervention.
We found that brain glucose metabolism is a notable determinant of cognitive decline progression, especially for Alzheimer's disease risk, providing quantifiable metabolic protection against decline. Our results demonstrate brain glucose hypometabolic findings from baseline FDG-PET as a precision biomarker for therapeutic stratification and support further interventions for cognitive preservation for further research, validation and development purposes that should be further evaluated and investigated in further clinical trials that may lead to better preventive and therapeutic benefits for cognitive functions preservation and prevention of cognitive decline process in high-risk individuals.
No takes yet. Share an insight, caveat, or question.
Alhasan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: